Skip to content

A-161 Correlation of Cardiovascular Disease and Diabetes to the Enhanced Liver Fibrosis Score

Oct 2026 · Clinical Chemistry · 0 citations

Abstract

Roughly 90% of patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have at least one feature of metabolic syndrome, a disease characterized by insulin resistance, obesity, hypertension and hyperlipidemia. MASLD can be accessed by the Enhanced Liver Fibrosis test (ELF, Siemens Healthineers), a noninvasive estimate of liver fibrosis, which is a calculated score that includes measurement of hyaluronic acid, amino-terminal pro-peptide of type III procollagen (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). We evaluated whether the presence of diabetes mellitus (DM) and/or cardiovascular disease (CVD) is associated with differences in ELF score. 203 remnant serum samples were retrieved from the Zuckerberg San Francisco General Hospital and 221 serum and plasma samples were retrieved from the Wexner Medical Center, Ohio State University (OSU). This study was approved by the IRB at the University of California San Francisco, and OSU, who deemed that informed consent was not required. Among the combined cohort, 129 samples had a confirmed diagnosis of DM, 58 with CVD, 60 with both, and 177 with neither disorder. Serum and plasma samples were tested for the following analytes: ELF, B-type natriuretic peptide (NT-proBNP), and high-sensitivity cardiac troponin (hs-TnI) using the Siemens Atellica IM analyzer. An ELF score of <9.80 indicates a low risk for disease progression (cirrhosis and liver-related events), = 9.80 to < 11.30 indicates a indicates an intermediate risk, and =11.30 suggests a higher risk. As some of the results exhibited a non-parametric distribution, the Wilcoxon test was used to determine statistical significance given the non-parametric data of the data. Categorical comparisons were evaluated using the chi-square test. A comparison of serum to plasma samples collected simultaneously showed a positive bias for PIIINP and a negative bias for TIMP-1, but no significant difference in the ELF score, therefore results for the two sample types were combined. An ELF score <9.80 was observed in 74% of patients without diabetes or CVD and 51% of patients with DM, CVD, or both. A score (9.80 – <11.30) was observed in 19.8% and 40.1% of patients, respectively. Finally, A ELF score (=11.30) was observed in 6.2% and 8.9% of patients, respectively (p < 0.001). Regarding the ELF score, patients with DM, or both also had higher median ELF scores (9.70, 9.70, and 9.80, respectively) than patients without either disorder (median 9.20, p<0.001, p<0.005 and p<0.001, respectively). As expected, hs-cTnI and NT-proBNP were significantly higher in CVD and combined groups. In this pilot cohort, the presence of DM and/or CVD was associated with modest but statistically significant increases in ELF score compared with individuals without these conditions. These findings suggest that ELF may reflect the broader metabolic and cardiovascular risk milieu in MASLD patients. Given the high frequency of liver fibrosis, integration of fibrosis biomarkers such as ELF and other fibrosis indices with traditional cardiometabolic markers (lipids, cardiac troponin or the natriuretic peptides) may improve the risk stratification of future adverse cardiac events.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.